Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 1, 2009, Pages 45-51

  Attia, Steven ^a   Morgan Meadows, Sherry ^b   Holen, Kyle D ^a   Bailey, Howard H ^a   Eickhoff, Jens C ^a   Schelman, William R ^a   Traynor, Anne M ^a   Mulkerin, Daniel L ^a   Campbell, Toby C ^a   McFarland, Thomas A ^a   Huie, Michael S ^a   Cleary, James F ^a   Tevaarwerk, Amye J ^a   Alberti, Dona B ^a   Wilding, George ^a   Liu, Glenn ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Gulf Coast Minority Based Clinical Oncology Program   (United States)

Author keywords

Capecitabine; Fixed dose rate; Gemcitabine; Phase I

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; PACLITAXEL; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BILE DUCT CARCINOMA; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PANCREAS CARCINOMA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 67349243468     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0844-1     Document Type: Article

References (26)

1. JL Abbruzzese R Grunewald EA Weeks D Gravel T Adams B Nowak S Mineishi P Tarassoff W Satterlee MN Raber 1991 A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 491 498
2. M Benekli R Yildiz A Uner O Er D Yamac N Alkis U Coskun C Camci S Buyukberber 2007 Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes Oncology 72 308 313
3. S Boeck T Hoehler G Seipelt R Mahlberg A Wein A Hochhaus HP Boeck B Schmid E Kettner M Stauch F Lordick Y Ko M Geissler K Schoppmeyer G Kojouharoff A Golf S Neugebauer V Heinemann 2008 Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer Ann Oncol 19 340 347
4. R Grunewald H Kantarjian M Du K Faucher P Tarassoff W Plunkett 1992 Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study J Clin Oncol 10 406 413
5. R Herrmann G Bodoky T Ruhstaller B Glimelius E Bajetta J Schuller P Saletti J Bauer A Figer B Pestalozzi CH Kohne W Mingrone SM Stemmer K Tamas GV Kornek D Koeberle S Cina J Bernhard D Dietrich W Scheithauer 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2212 2217 (Pubitemid 46954645)
6. V Hess M Salzberg M Borner R Morant AD Roth C Ludwig R Herrmann 2003 Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial J Clin Oncol 21 66 68
7. JJ Knox D Hedley A Oza R Feld LL Siu E Chen M Nematollahi GR Pond J Zhang MJ Moore 2005 Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 2332 2338 (Pubitemid 46218726)
8. M Mackean A Planting C Twelves J Schellens D Allman B Osterwalder B Reigner T Griffin S Kaye J Verweij 1998 Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer J Clin Oncol 16 2977 2985 (Pubitemid 28417417)
9. M Miwa M Ura M Nishida N Sawada T Ishikawa K Mori N Shimma I Umeda H Ishitsuka 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281 (Pubitemid 28342121)
10. MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden PP Carbone 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649 655 (Pubitemid 13149996)
11. BB Park JO Park HR Lee J Lee DW Choi SH Choi JS Heo JK Lee KT Lee H Lim do YS Park HY Lim WK Kang K Park 2007 A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma Cancer Chemother Pharmacol 60 489 494 (Pubitemid 47084257)
12. E Poplin D Levy J Berlin M Rothenberg D Cella E Mitchell S Alberts A Benson 2006 Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201) Proc Am Soc Clin Oncol 24 4004
13. RP Riechelmann CA Townsley SN Chin GR Pond JJ Knox 2007 Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer Cancer 110 1307 1312 (Pubitemid 47435603)
14. BI Rini V Weinberg EJ Small 2005 A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma Cancer 103 553 558
15. Santini D, Vincenzi B, Masi G, Catalano V, Virzi V, Fontana A, Vasile E, Intagliata S, Catalano G, Falcone A, Tonini G (2008) Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer. J Clin Oncol 26, May 20 Suppl, Abstract 15596
16. Santini D, Vincenzi B, Masi G, Catalano V, Virzi V, Vasile E, Intagliata S, Catalano G, Falcone A, Tonini G (2008) Fixed dose rate (FDR) gemcitabine (G) and capecitabine (C) in patients with metastatic biliary tract cancer (BTC): phase II trial. 2008 Gastrointestinal Cancers Symposium, Abstract No. 223
17. D Santini V Virzi B Vincenzi L Rocci V Leoni G Tonini 2007 A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients Ann Oncol 18 576 580 (Pubitemid 46359642)
18. RL Schilsky D Bertucci NJ Vogelzang HL Kindler MJ Ratain 2002 Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer J Clin Oncol 20 582 587 (Pubitemid 34072543)
19. J Schuller J Cassidy E Dumont B Roos S Durston L Banken M Utoh K Mori E Weidekamm B Reigner 2000 Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 291 297 (Pubitemid 30151522)
20. SA Schulz L W Wilmanns 1998 Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells Proc Am Soc Clin Oncol 17 965
21. R Simon B Freidlin L Rubinstein SG Arbuck J Collins MC Christian 1997 Accelerated titration designs for phase I clinical trials in oncology J Natl Cancer Inst 89 1138 1147 (Pubitemid 27337928)
22. WM Stadler S Halabi B Rini MS Ernstoff E Davila J Picus R Barrier EJ Small 2006 A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008 Cancer 107 1273 1279 (Pubitemid 44452776)
23. BE Storer 1989 Design and analysis of phase I clinical trials Biometrics 45 925 937 (Pubitemid 19249331)
24. M Tempero W Plunkett V Ruiz Van Haperen J Hainsworth H Hochster R Lenzi J Abbruzzese 2003 Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 3402 3408 (Pubitemid 46594072)
25. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
26. JS Waters C Moss L Pyle M James S Hackett R A'Hern M Gore T Eisen 2004 Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma Br J Cancer 91 1763 1768 (Pubitemid 39664962)